Evaluation of the drug interaction between intravenous high-dose fluconazole and cyclosporine or tacrolimus in bone marrow transplant patients

Transplantation
C L OsowskiJ R Wingard

Abstract

The purpose of this open-label, prospective study was to compare steady state concentrations and clearances of intravenously administered cyclosporine or tacrolimus with and without concomitant high-dose (400 mg/day) fluconazole in allogeneic BMT patients. Twenty-one patients were evaluable. The mean steady state cyclosporine and tacrolimus concentrations without fluconazole were 320.3 and 18.2 ng/ml and increased to 389.2 and 21.2 ng/ml, respectively, after the addition of fluconazole, corresponding to a 21% (P=0.031) and 16% (P=0.125) increase. The mean steady state clearance of cyclosporine and tacrolimus without fluconazole was 6.82 and 1.28 ml/min/kg, which decreased to 5.57 and 1.10 ml/min/kg with fluconazole, corresponding to a 21% (P=0.031) and 16% (P=0.125) decrease, respectively. The 21% difference in the cyclosporine concentration and clearance was not thought to be clinically significant. These results suggest that fluconazole's interaction with cyclosporine or tacrolimus may be a result of fluconazole's inhibition of gut metabolism, resulting in a greater extent of absorption.

References

Mar 1, 1992·Antimicrobial Agents and Chemotherapy·J E WallaceM G Rinaldi
Jan 1, 1990·Pharmacotherapy·S F Kowalsky
Nov 1, 1990·Seminars in Liver Disease·P B Watkins
Mar 1, 1990·Reviews of Infectious Diseases·J D Lazar, K D Wilner
Nov 1, 1989·The Journal of Antimicrobial Chemotherapy·H U KrügerG Ehninger
May 27, 1994·Transplantation·R MañezT E Starzl
Apr 1, 1993·The Annals of Pharmacotherapy·J A López-Gil

❮ Previous
Next ❯

Citations

Jul 30, 1999·Journal of the American Academy of Dermatology·A K GuptaN H Shear
Mar 7, 2000·The Journal of Heart and Lung Transplantation : the Official Publication of the International Society for Heart Transplantation·S RhieB Suh
Jun 29, 2001·Transplant Infectious Disease : an Official Journal of the Transplantation Society·J StrahilevitzD Engelhard
Jun 19, 2010·Clinical Chemistry and Laboratory Medicine : CCLM·Marie-Clémence VerdierEric Bellissant
Mar 10, 2000·Clinical Pharmacokinetics·K VenkatakrishnanD J Greenblatt
May 23, 2001·Clinical Pharmacokinetics·P E Wallemacq, R K Verbeeck
Jul 28, 2001·Clinical Pharmacokinetics·D Debruyne, A Coquerel
Aug 23, 2002·Clinical Pharmacokinetics·Uwe ChristiansAlfonso Lampen
Jul 28, 2012·Stem Cell Reviews and Reports·S Abdul Wahid Fadilah, Md Pazil Aqilah
Oct 7, 2008·The Journal of Antimicrobial Chemotherapy·R Y HachemI I Raad
Sep 22, 2005·Therapeutic Drug Monitoring·Eva M VasquezEnrico Benedetti
Nov 17, 2004·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·John R Wingard
Nov 23, 2006·Cancer Investigation·Rachel P Riechelmann, Everardo D Saad
Feb 26, 2016·Drug Metabolism Reviews·Thomas VanhoveDirk R J Kuypers
Jun 5, 2007·Pharmacotherapy·Angela Sansone-ParsonsTim G Mant
Oct 16, 2012·Clinical Transplantation·Magdalena B SikoraFuad S Shihab
Dec 17, 2009·Mycoses·Paul O Gubbins, Seth Heldenbrand
Feb 24, 2015·Transplant Infectious Disease : an Official Journal of the Transplantation Society·S K HegazyN M Khalafallah
Nov 7, 2012·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·L Lee DupuisTal Schechter
Oct 13, 2005·Expert Opinion on Pharmacotherapy·Paul O Gubbins, Jarrett R Amsden
Dec 14, 2011·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Brett GlotzbeckerRobert Soiffer
Mar 1, 2006·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Helen LeatherJohn R Wingard
Jan 16, 2007·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Timothy MaddenBorje S Andersson
Jul 1, 1997·Clinical Pharmacology and Therapeutics·L C FlorenM F Hebert
Feb 11, 2000·The Annals of Pharmacotherapy·R Y ChenhsuW C Yang
Nov 28, 2018·Expert Opinion on Drug Metabolism & Toxicology·Ana PejčićMiloš Milosavljević
Oct 10, 2019·Expert Opinion on Drug Metabolism & Toxicology·Yuan Gao, Jingjing Ma

❮ Previous
Next ❯

Related Concepts

Related Feeds

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.